

AMENDMENTS TO THE SPECIFICATION

Page 1, line 7, after "CROSS REFERENCE TO RELATED APPLICATIONS" please amend as shown:

~~This patent application claims priority from Provisional Patent Application 60/03915 filed on February 20, 1997.~~

This application is a continuation application under 37 CFR 1.53(b) and 1.78(a), of and claims priority to pending prior parent United States Patent Application serial number 09/367,712, filed August 18, 1999, which is a national stage application of PCT/US98/03355, filed February 20, 1998, which claimed priority to United States Provisional Patent Application 30/03915, file on February 27, 1997 for TAZAROTENE AND CORTICOSTEROID TREATMENT FOR PSORIASIS. The disclosures of all of these priority documents are expressly incorporated by reference herein.